The DOI matches its Crossref record.
Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome
Abstract
INTRODUCTION: A recent pilot study noted clinical benefit of macrolide therapy in the management of six lung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition previously regarded as irreversible. OBJECTIVE: To examine the effect of low-dose macrolides on lung function in lung allograft recipients with established BOS and to assess whether this benefit is sustained. METHODS: We retrospectively evaluated the effect of azithromycin (250 mg alternate days) on clinical status and lung function in 20 allograft recipients with established BOS, confirmed by decline in FEV(1) or FEF(25-75); consistent high-resolution computed tomography findings; and exclusion of acute rejection, infection, or anastomatic complications. Azithromycin was introduced at mean 82 months after transplantation. BOS staging at initiation of treatment was BOS 3 (10), BOS 2 (2), BOS 1 (6), and BOS0-p (2). All patients were on maintenance immunosuppression comprising cell-cycle inhibitor, oral corticosteroids, and calcineurin inhibitor. RESULTS: There was a significant increase in FEV(1) of median 110 ml (range, -70 to 730 ml) between baseline and 3 months of azithromycin therapy (p = 0.002). This improvement was sustained beyond 3 months in the majority of patients, who had initially benefited from azithromycin (up to 11 months follow up). CONCLUSIONS: This case series confirms the benefit of azithromycin in not only halting, but reversing the declining lung function seen in patients with BOS. This benefit appears to be maintained over time. Low-dose macrolides offer a new and exciting therapeutic strategy for the treatment of progressive BOS, and further clinical and translational mechanistic studies are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications
Kanoh, S., & Rubin, B. K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-09 · Cited by 708
Meyer, K. C., Raghu, G., Verleden, G. M., Corris, P. A., Aurora, P., Wilson, K. C., Brozek, J., Glanville, A. R., & the ISHLT/ATS/ERS BOS Task Force Committee (2014) · European Respiratory Journal · doi:10.1183/09031936.00107514 · Cited by 555
Self-citationA new classification system for chronic lung allograft dysfunction
Verleden, G. M., Raghu, G., Meyer, K. C., Glanville, A. R., & Corris, P. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.10.022 · Cited by 503
Self-citationCytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
Self-citationAzithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection
Renna, M., Schaffner, C., Brown, K., Shang, S., Tamayo, M. H., Hegyi, K., Grimsey, N. J., Cusens, D., Coulter, S., Cooper, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46095 · Cited by 314
Metadata
- Authors
- Yates, B., Murphy, D. M., Forrest, I. A., Ward, C., Rutherford, R. M., Fisher, A. J., Lordan, J. L., Dark, J. H., & Corris, P. A.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-15
- Volume
- 172
- Issue
- 6
- Pages
- 772-775
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2164136965
- Cited by
- 228
- References
- 0
- FWCI
- 16.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome. https://app.cochat.ai/papers/10.1164/rccm.200411-1537oc
- The paper
- Yates, B., Murphy, D. M., Forrest, I. A., Ward, C., Rutherford, R. M., Fisher, A. J., Lordan, J. L., Dark, J. H., & Corris, P. A. (2005). Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200411-1537oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.